<DOC>
	<DOC>NCT00076011</DOC>
	<brief_summary>The primary purpose of this protocol is to determine the activity of AG 013736 in patients with metastatic renal cell cancer who have received 1 prior cytokine-based therapy.</brief_summary>
	<brief_title>Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Histologically documented RCC with metastases. Failure of 1 prior cytokinebased therapy (interleukin2 and/or interferon) due to disease progression or unacceptable treatmentrelated toxicity Any prior systemic treatment for Renal Cell Carcinoma [RCC] other than 1 prior cytokinebased treatment regimen. Cytokinebased regimens containing thalidomide or an antiangiogenesis agent are not allowed. Inability to take oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>